Heme Triggers TLR4 Signaling Leading to Endothelial Cell Activation and Vaso-occlusion in Murine Sickle Cell Disease
Overview
Authors
Affiliations
Treatment of sickle cell disease (SCD) is hampered by incomplete understanding of pathways linking hemolysis to vaso-occlusion. We investigated these pathways in transgenic sickle mice. Infusion of hemoglobin or heme triggered vaso-occlusion in sickle, but not normal, mice. Methemoglobin, but not heme-stabilized cyanomethemoglobin, induced vaso-occlusion, indicating heme liberation is necessary. In corroboration, hemoglobin-induced vaso-occlusion was blocked by the methemoglobin reducing agent methylene blue, haptoglobin, or the heme-binding protein hemopexin. Untreated HbSS mice, but not HbAA mice, exhibited ∼10% vaso-occlusion in steady state that was inhibited by haptoglobin or hemopexin infusion. Antibody blockade of adhesion molecules P-selectin, von Willebrand factor (VWF), E-selectin, vascular cell adhesion molecule 1, intercellular adhesion molecule 1, platelet endothelial cell (EC) adhesion molecule 1, α4β1, or αVβ3 integrin prevented vaso-occlusion. Heme rapidly (5 minutes) mobilized Weibel-Palade body (WPB) P-selectin and VWF onto EC and vessel wall surfaces and activated EC nuclear factor κB (NF-κB). This was mediated by TLR4 as TAK-242 blocked WPB degranulation, NF-κB activation, vaso-occlusion, leukocyte rolling/adhesion, and heme lethality. TLR4(-/-) mice transplanted with TLR4(+/+) sickle bone marrow exhibited no heme-induced vaso-occlusion. The TLR4 agonist lipopolysaccharide (LPS) activated ECs and triggered vaso-occlusion that was inhibited by TAK-242, linking hemolysis- and infection-induced vaso-occlusive crises to TLR4 signaling. Heme and LPS failed to activate VWF and NF-κB in TLR4(-/-) ECs. Anti-LPS immunoglobulin G blocked LPS-induced, but not heme-induced, vaso-occlusion, illustrating LPS-independent TLR4 signaling by heme. Inhibition of protein kinase C, NADPH oxidase, or antioxidant treatment blocked heme-mediated stasis, WPB degranulation, and oxidant production. We conclude that intravascular hemolysis in SCD releases heme that activates endothelial TLR4 signaling leading to WPB degranulation, NF-κB activation, and vaso-occlusion.
Trained immunity causes myeloid cell hypercoagulability.
Rehill A, McCluskey S, Ledwith A, Ryan T, Unlu B, Leon G Sci Adv. 2025; 11(10):eads0105.
PMID: 40053582 PMC: 11887800. DOI: 10.1126/sciadv.ads0105.
Targeting sickle cell pathobiology and pain with novel transdermal curcumin.
Goel Y, Arellano M, Fouda R, Garcia N, Lomeli R, Kerr D PNAS Nexus. 2025; 4(2):pgaf053.
PMID: 40007577 PMC: 11854080. DOI: 10.1093/pnasnexus/pgaf053.
Mikhailova D, Sudnitsyna J, Kovgan P, Naida L, Kharazova A, Mindukshev I Cells. 2025; 14(4).
PMID: 39996728 PMC: 11853094. DOI: 10.3390/cells14040255.
Trained innate immunity as a potential link between preeclampsia and future cardiovascular disease.
Carrasco-Wong I, Sanchez J, Gutierrez J, Chiarello D Front Endocrinol (Lausanne). 2025; 15:1500772.
PMID: 39741876 PMC: 11685753. DOI: 10.3389/fendo.2024.1500772.
Inflammatory pathways and anti-inflammatory therapies in sickle cell disease.
Tozatto-Maio K, Ros F, Weinlich R, Rocha V Hemasphere. 2024; 8(12):e70032.
PMID: 39698332 PMC: 11655128. DOI: 10.1002/hem3.70032.